Displacing an entrenched blockbuster drug requires defeating it in a direct, head-to-head trial.
To bypass competitor advantages and secure market dominance, drug developers are increasingly running Phase 3 trials designed to clinically demonstrate clear superiority directly against established treatment standards.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
To establish a dominant market presence for its new oral GLP-1, Eli Lilly launched a head-to-head Phase 3 trial directly proving superior weight loss over oral semaglutide.
Takeda positioned zasocitinib to displace Sotyktu by validating its clinical superiority in a rigorous head-to-head Phase 3 plaque psoriasis trial.
The post-immunotherapy kidney-cancer slot was taken by beating the entrenched standard head-to-head on progression-free survival.
Tam-Peli established itself as a breakthrough in relapsed SCLC by demonstrating clear superiority in a direct Phase 3 comparison against the long-standing standard treatment.
Unseating the entrenched immunotherapy standard required beating it directly in a randomized head-to-head Phase 3 on survival.
Sanofi is using the newly approved subcutaneous hands-free delivery system of Sarclisa to challenge and displace J&J's dominant blockbuster competitor in the myeloma market.
Developers of this novel bispecific antibody proved its commercial potential by directly challenging and defeating the current clinical standard of care in a head-to-head trial.
The finding presents a new drug seeking market dominance by launching directly head-to-head against an entrenched competitor with a broader label spanning multiple disease settings.